期刊文献+

中晚期非小细胞肺癌中医证型与吉非替尼治疗敏感性关系研究 被引量:16

下载PDF
导出
摘要 目的:研究探讨Ⅲ、Ⅳ期非小细胞肺癌患者吉非替尼治疗敏感性与中医证型分布的关系。方法:共入选Ⅲ、Ⅳ期符合标准的非小细胞肺癌患者84例,于吉非替尼治疗前行中医辨证分型,吉非替尼治疗后1个月观察各证型治疗后反应率。结果:肺脾两虚型治疗后缓解率为:83.33%,气阴两虚型治疗后缓解率为89.47%,阴虚内热型治疗后缓解率为59.10%,痰湿瘀阻肺肾亏虚型治疗后缓解率为27.78%。各组之间两两比较肺脾气虚型与气阴两虚型之间有效率无差异(P=0.136),肺脾气虚型与阴虚内热型、痰湿瘀阻肺肾亏虚型有效率有差异(P<0.05)。气阴两虚型与阴虚内热型、痰湿瘀阻肺肾亏虚型有效率有差异(P<0.05);阴虚内热型与痰湿瘀阻肺肾亏虚型之间有效率差异有意义(P<0.05)。结论:中晚期非小细胞肺癌中医证属气阴两虚、肺脾气虚者对吉非替尼治疗有效率较其它类型为高,此两种证型对吉非替尼治疗的敏感性高于其它证型。
出处 《辽宁中医杂志》 CAS 北大核心 2009年第6期867-869,共3页 Liaoning Journal of Traditional Chinese Medicine
  • 相关文献

参考文献11

  • 1PAO W, MILLER VA. Epjdennal growth factor receptor muta-lions, small-moletale kinase inhlbitors, and non-small-cell lung cancer: carrent knowledge and future directions [ J ]. J Clin Oncol, 2005,23 ( 11 ) :2556 -2568. 被引量:1
  • 2陈玲,陈强,叶韵斌.吉非替尼敏感性预测指标的研究现状[J].中国新药与临床杂志,2006,25(11):864-868. 被引量:9
  • 3FUKuoKA M ,Y. ANO S,GLACCONE G,et al. Multi-institutional ran- domized phasell trial of geGtinib for preViously treated patients with advanted non-smallcell lung canoe[J]. J Clin Oncol,2003,21 (12) : 2237 - 2246. 被引量:1
  • 4KRJs MG NATALE RB,HERBST Rs,et al. EfGca < :y of gcfitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer a randomized trial[J]. JAMA,2003,290(16) :2149 -2158. 被引量:1
  • 5OCHS J, GROLiS JJ. WARNF. R K1, et al. Final survival and safety results for 21064. non-mall-cell lung cancer(NSCLC) pabents who received compassionate USe gefitinib in a US expanded aceess program (EAP) [ J]. Proc Am Soc Clin Oncol 2004,23:628 ( Abstr 7060). 被引量:1
  • 6PAEZ JG,JANNE PA ,LE EJC,et al. EGFR mutations in lung cancer: correlation wifll clinical response to gefitinib therapy [ J ]. scienee, 2004,304(5676) :1497 - 1500. 被引量:1
  • 7LYNCH TJ,BELL DW,SORDEI T A R,et al. ActiVating mutatiorls in the ePidermal growth facror receptor Haderlying responsivenes, ofnon small celllilng cantertogefitinlb [ J ]. N Engl J Med, 2004,350 ( 21 ) : 2129 -2139. 被引量:1
  • 8cAPpuzzo F, HIRseH FR, ROSSLE, et al. Epidermal growth factor reeptor gene and Protein and gefitinib sensitivity in non-small cell lung cancer[ J ]. Nail Cancer Ins,2005,97 ( 9 ) :643 - 655. 被引量:1
  • 9OKAMOTO T,NAKAMuRA T,IKEDA J,IKEDAJ. et al. Sernum carcinostnbwonie antigen as apredctive marker for sensitivity to gefitinib inadvanced non smaller lung cancer[J]. Eur J Caneer,2005,4.1 (9) : 1286 - 1290. 被引量:1
  • 10ISHIKAWAN, DAIGOY ,TAKANOA, et al. Increases of amPhiregUlin and transforminggrowth factor-(alPha) in serum as Predietors f poor responsc to gentinib among patients with advanced non smaller lung cancers[J]. Cancer Res,2005,65 (20) :9176 -9184. 被引量:1

二级参考文献27

  • 1ISHIKAWA N, DAIGO Y, TAKANO A, et al, Increases of amphiregulin and transforming growth factor-{alpha} in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers[J]. Cancer Res, 2005, 65(20) :9176-9184. 被引量:1
  • 2HERBST RS, KIES MS. ZD1839 (lressa) in non-small-cell lung cancer[J]. Oncologist, 2002, 7 Suppl 4:S9-S15. 被引量:1
  • 3IWASAWA A, KUMAMOTO Y, FUJINAGA K. Detection of human papillomavirus deoxyribonucleic acid in penile carcinoma by polymerase chain reaction and in situ hybridization[J]. J Urol,1993, 149 ( 1 ) : 59-63. 被引量:1
  • 4VARMA VA, SANCHEZ-LANIER M, UNGER ER, et al. Association of human papillomavirus with penile carcinoma: a study using polymerase chain reaction and in situ hybridization[J]. Hum Pathol, 1991, 22(9):908-913. 被引量:1
  • 5GORGOULIS V. ANINOS D, MIKOU P. et al, Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas[J]. Anti Cancer Res, 1992, 12(4): 1183-1187. 被引量:1
  • 6RANSON M, HAMMOND LA, FERRY D, et al. ZD1839, a selective oral EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumours: results of a phase 1 trial[J]. J Clin Oncol, 2002, 20(9) :2240-2250. 被引量:1
  • 7HERBST RS, MADDOX AM, ROTHENBERG ML, et al, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial[J], J Clin Oncol, 2002, 20(18):3815-3825. 被引量:1
  • 8BASELGA J, RISCHIN D, RANSON M, et al. Phase I safety,pharmacokinetic, and pharmaeodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyroslne kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002, 20(21 ) :4292-4302. 被引量:1
  • 9LORUSSO PM, HERBST RS, RISCHIN D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinasc inhibitor ZD1839 in non-small cell lung cancer and other solid tumors[J]. Clin Cancer Res, 2003, 9(6):2040-2048. 被引量:1
  • 10KRIS MG, NATALE RB, HERBST RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer[J]. JAMA, 2003, 290(16):2149-2158. 被引量:1

共引文献8

同被引文献230

引证文献16

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部